Close

Amgen (AMGN) Plans Presentation of New IMLYGIC Combo Data in Metastatic Colorectal Cancer at ESMO 2016

Go back to Amgen (AMGN) Plans Presentation of New IMLYGIC Combo Data in Metastatic Colorectal Cancer at ESMO 2016

New Amgen Data In Melanoma And Metastatic Colorectal Cancer To Be Presented At The European Society For Medical Oncology 2016 Congress

October 5, 2016 4:10 PM EDT

THOUSAND OAKS, Calif., Oct. 5, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new data on IMLYGIC® (talimogene laherparepvec) in combination with an immune checkpoint inhibitor and results from retrospective analyses on Vectibix® (panitumumab) will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress, Oct. 7-11, 2016, in Copenhagen.

IMLYGIC presentations include interim results from a Phase 2 trial evaluating IMLYGIC in combination with ipilimumab versus ipilimumab alone in patients with unresected stage IIIB-IV melanoma. Vectibix abstracts include retrospective analyses of the first-line Phase 3 PRIME and PEAK studies, evaluating the... More